Search hospitals > Arizona > Scottsdale

HonorHealth Research Institute

Claim this profile
Scottsdale, Arizona 85258
Global Leader in Pancreatic Cancer
Global Leader in Solid Tumors
Conducts research for Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
152 reported clinical trials
14 medical researchers
Photo of HonorHealth Research Institute in ScottsdalePhoto of HonorHealth Research Institute in ScottsdalePhoto of HonorHealth Research Institute in Scottsdale

Summary

HonorHealth Research Institute is a medical facility located in Scottsdale, Arizona. This center is recognized for care of Pancreatic Cancer, Solid Tumors, Cancer, Lung Cancer, Colorectal Cancer and other specialties. HonorHealth Research Institute is involved with conducting 152 clinical trials across 257 conditions. There are 14 research doctors associated with this hospital, such as Vincent Chung, MD, Michael S Gordon, MD, Sunil Sharma, and Erkut Borazanci, MD.

Area of expertise

1Pancreatic Cancer
Global Leader
HonorHealth Research Institute has run 53 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
Stage III
metastatic
2Solid Tumors
Global Leader
HonorHealth Research Institute has run 50 trials for Solid Tumors. Some of their research focus areas include:
Stage IV
Stage III
metastatic

Top PIs

Clinical Trials running at HonorHealth Research Institute

Pancreatic Cancer
Lung Cancer
Solid Tumors
Colorectal Cancer
Breast Cancer
Melanoma
Non-Small Cell Lung Cancer
Cancer
Ovarian Cancer
Myasthenia Gravis
Image of trial facility.

Ivaltinostat + Capecitabine

for Pancreatic Cancer

This trial tests ivaltinostat with capecitabine in patients with advanced pancreatic cancer who have not worsened after initial treatment. The goal is to find a safe and effective dose and to see if this combination can better control the cancer. Capecitabine is a medication that is converted into another drug in the body, showing better selectivity and tolerability in tumor tissues.
Recruiting3 awards Phase 1 & 211 criteria
Image of trial facility.

LY4170156

for Breast Cancer

The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Recruiting1 award Phase 11 criteria
Image of trial facility.

RAS(ON) Inhibitors

for Gastrointestinal Cancer

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel
Recruiting1 award Phase 1 & 24 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at HonorHealth Research Institute?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security